Methods and Means Related to Cancer Stem Cells

ABSTRACT

This invention relates to the methods for the identification and isolation of cancer stem cells from cultured cancer cell lines. Cell line-derived cancer stem cells isolated using the present methods may be useful, for example, in assays to screen compounds for anti-cancer stem cell activity and in target discovery methods for identifying novel expressed genes and druggable targets. The invention also relates to the screening of compounds for activity against cell line-derived cancer stem cells.

This application is a divisional of U.S. patent application Ser. No.11/667,819, filed Sep. 28, 2007, which is a National Stage Applicationof International Application No. PCT/IB2005/003386, filed Nov. 12, 2005,which is entitled to and claims priority benefit to U.S. ProvisionalApplication No. 60/627,639, filed Nov. 12, 2004, each of which isincorporated by reference in their entireties.

FIELD OF THE INVENTION

This invention relates to the identification and isolation of cancerstem cells and the use of the isolated cancer stem cells in assays toscreen compounds for anti-cancer stem cell activity and in targetdiscovery methods for identifying novel expressed genes and druggabletargets

BACKGROUND OF THE INVENTION

U.S. Pat. No. 6,004,528, incorporated herein by reference, disclosesthat cancer lesions contain a small but highly virulent sub-populationof abnormal stem cells and that these “cancer stem cells” play asignificant role in the malignancy of the cancer and in the resistanceof the cancer to many standard therapies. Cancer stem cells have beenidentified, for example, in acute myeloid leukemia (Jordan, C. T., et al(2000) Leukemia 14, 1777-1784), chronic myeloid leukemia (Jamieson, C.H. M., et al (2004) N Engl J Med 351, 657-667), breast cancer (Al-Hajj,M. et al (2003) Proc. Natl. Acad. Sci. USA 100, 3983-3988), brain cancer(Singh, S. K. et al (2003) Cancer Res 63, 5821-5828), multiple myeloma(Matsui, W., et al (2004) Blood 103, 2332-2336), and other cancer types.

The presence of cancer stem cells may lead to recurrences of cancerafter treatment. To prevent recurrences, cancer therapies need toeliminate cancer stem cells (Reya T., et al (2001) Nature 414, 105-111).

Stem cells in any tissue, whether normal or malignant, are present invery small numbers and they are difficult to identify and even moredifficult to isolate. There is a pressing need for methods to identifyand isolate cancer stem cells so that their gene expression profiles,potential drug targets, and properties may be characterized, includingtheir sensitivity to various anti-cancer therapeutic agents and newagents identified through rational drug design or drug screens.

The present invention addresses these and other needs in the art byproviding methods for identifying cancer stem cell genes and geneproducts, i.e., targets, which in turn provide tools for drug discovery,and molecules that identify a cancer cell as a cancer stem cell, e.g.,for targeting antibodies. The invention also provides assay systems fordiscovering or evaluating anti-cancer stem cell-based cancertherapeutics.

SUMMARY OF THE INVENTION

The present inventor has discovered that established cancer cell linesare not homogeneous, even when they have been maintained in culture overextended periods. A sub-population of cells, termed side population(SP), that have stem cell properties can be isolated from establishedcancer cell lines based on their exclusion of the dye Hoechst 33342.These cell line-derived cancer stem cells act as surrogates for primarytumor-derived cancer stem cells. This finding, i.e. that cancer celllines harbor cancer stem cell-like SP cells, has subsequently beenreplicated in the art (Matsui et al (2004) Blood 103: 2332-2336;Hirschmann-Jax et al (2004) PNAS USA 101: 14228-14233; Patrawala et al(2005) Cancer Res 65:6207-6219).

Accordingly, the present invention provides methods for identifyingand/or obtaining a cell line-derived cancer stem cell comprisingproviding a population of cancer cells from a cultured cancer cell line,e.g., a human cancer cell line, and determining the presence of a stemcell marker in one or more cells in the population, the presence and/orexpression level and/or amount of the marker being indicative that theone or more cells are cell line-derived cancer stem cells. In oneexample, the cell line-derived cancer stem cell is present in a breastcancer cell line, e.g., MCF-7 or an adenocarcinoma cell line.

Cancer stem cell markers include a verapamil or reserpine sensitive ATPbinding cassette (ABC) transporter, e.g., BCRP, or a molecule involvedin the Notch, Wnt, or Hedgehog pathway, e.g., Wnt10, Wnt11, Notch 1,Notch 2, or Notch 3. In specific embodiments, the cancer stem cellmarker is selected from the group consisting of prominin-1, BCRP, andCD133.

The cell line-derived cancer stem cells identified as described hereinmay be isolated and/or purified, e.g., by flow cytometry.

Another aspect of the invention provides methods for maintaining and/orculturing one or more cell line-derived cancer stem cells in a serumfree medium comprising PDGF and bFGF.

Still another aspect of the invention provides methods of identifying acancer stem cell marker comprising comparing the expression of one ormore nucleic acid molecules in a cell line-derived cancer stem cell withthe expression of the one or more nucleic acids in a non-stem cell ornormal stem cell or cancer cell that is not a cancer stem cell (a.k.a.tumor bulk), and identifying a nucleic acid molecule whose expression ismodulated, e.g., increased in the cell line-derived cancer stern cellrelative to the non-stem cell or normal stem cell or tumor bulk as acancer stem cell marker. In one embodiment, the cancer stem cell iscontacted with a test compound and the level and/or expression of thecancer stem cell marker nucleic acid molecule is determined.

The invention also provides methods of identifying a cancer stem cellmarker comprising comparing the level or amount of one or morepolypeptides in a cell line-derived cancer stem cell with the level oramount of one or more polypeptides in a non-stein cell or normal stemcell or tumor bulk, and identifying a polypeptide from the one or morepolypeptides whose level or amount is modulated, e.g., increased in thecancer stem cell relative to the non-stein cell or normal stem cell ortumor bulk as a cancer stem cell marker polypeptide. In one embodiment,the invention provides methods for producing an antibody that binds tothe identified cancer stem cell marker polypeptide.

Drug screens typically employ cancer cell lines, or some derivativethereof, and this process selects for compounds which target the bulk ofthe cell line, not the cell line-derived cancer stein cellsub-population. Cell line-derived cancer stem cells identified andpurified as described herein are therefore useful in the development ofmore effective cancer therapies.

In a further aspect, the invention provides methods of identifyingand/or obtaining a compound having anti-cancer stem cell activity foruse in the treatment of a cancer condition comprising contacting a cellline-derived cancer stem cell isolated by a method described herein witha test compound, and determining preferential binding of the testcompound to the cell line-derived cancer stem cell. In one embodiment,an increase in binding to the cell line-derived cancer stem cellrelative to a non-stem cell or normal cell is indicative that thecompound is useful in the treatment of a cancer condition.

In another aspect, the invention provides methods of identifying and/orobtaining a compound for use in the treatment of a cancer conditioncomprising contacting a cell line-derived cancer stem cell with a testcompound, and determining modulation of growth, proliferation,viability, and/or differentiation status of the cell in the presence ofthe test compound as compared to the growth, proliferation, viability,and/or differentiation status of a cell line-derived cancer stem cell inthe absence of the compound. In one embodiment, a decrease in growth,viability, and/or proliferation of the cell line-derived cancer stemcell is indicative that the compound is useful in the treatment of acancer condition. In another embodiment, the test compound is anantibody or a small molecule. In yet another embodiment, the method is ahigh throughput screening method.

Other features and advantages of the instant invention will be apparentfrom the following detailed description and examples which should not beconstrued as limiting. The contents of all references, Accessionnumbers, Genbank entries, patents and published patent applicationscited throughout this application are expressly incorporated herein byreference.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A-1H show the existence of SP cells in established cancer celllines. Cells of the rat C6 glioma (A, E), human MCF7 breast carcinoma(B, F), rat B104 neuroblastoma (C, G), and human HeLa carcinoma (D, H)cell lines were labeled with Hoechst 33342 and then analyzed by flowcytometry. (E-H) Results when the cells were treated with 50-μMverapamil during the labeling procedure are also shown. The SP, whichdisappears in the presence of verapamil, is outlined and shown as apercentage of the total cell population. These experiments were repeatedat least three times with similar results.

FIGS. 2A-2H show the roles of PDGF and bFGF on C6 SP cells. C6 SP cellswere cultured for 3 weeks in FCS (A, E) or serum-free medium with bFGF(B, F), PDGF (C, G), or both (D, H) and were analyzed by flow cytometryas shown in FIG. 1. (E-H) Results when the cells were treated with 50-μMverapamil during the labeling procedure. All experiments were repeatedat least three times with similar results.

FIG. 3 shows the roles of PDGF and bFGF on C6 SP cells. C6 cells werecultured in FCS (open circle), bFGF (closed triangle), PDGF (closedsquare), or bFGF plus PDGF (closed circle) for the indicated times, andthe proportion of SP cells was analyzed by flow cytometry. Allexperiments were repeated at least three times with similar results.

FIGS. 4A-4F show the different roles of bFGF and PDGF on C6 SP cells. C6cells were cultured in PDGF (A, D), bFGF (B, E), or both (C, F) for 2weeks and then expanded in bFGF plus PDGF for an additional 2 weeks inthe presence (D-F) or absence (A-C) of verapamil. They were thenanalyzed by flow cytometry as described for FIG. 1. All experiments wererepeated at least three times with similar results.

FIG. 5 shows that SP cells in the C6 glioma cell line can generate bothSP and non-SP C6 cells. C6 cells were cultured in bFGF plus PDGF for 2weeks and then sorted by flow cytometry as described for FIG. 1. The SPand non-SP cells were then cultured separately in the same conditionsfor an additional 2 weeks. The cells were then analyzed by flowcytometry as shown in FIG. 1.

FIG. 6 shows evidence of malignancy of C6 SP cells in vivo. SP or non-SPC6 cells (10⁵) were injected i.p. into 4-week-old female nude mice. Themice were killed 18 d later and the hematocrit was measured.

FIGS. 7A-7D show the roles of EGF and bFGF on MCF7 SP cells. The cellswere cultured in FCS (A) or serum-free medium with bFGF (B), EGF (C), orboth (D) for 7 days and were analyzed by flow cytometry. The SP isoutlined and shown as a % of the total cell population.

FIG. 8A-8E shows the results of a comparative study of the geneexpression profiles of cancer stem cells and non-cancer stem cells ofthe human breast cancer cell line, MCF-7, and identifies gene productsthat are differentially expressed by cancer stem cells. SP and non-SPcells were isolated as described above, and RNA was prepared asdescribed. Expression of genes associated with the Wnt (8A), Notch (8B),and Hedgehog (HH) (8C) pathways, as well as a variety of stem cell (8D)and differentiation markers (8E), was assessed by RT-PCR using genespecific primers.

FIG. 9A-9H shows that cancer stem cells within the cancer cell lineMCF-7 can be identified using monoclonal antibodies specific for cellsurface proteins. SP and non-SP cells were isolated by flow cytometry.Cells were fixed in paraformaldehyde and incubated withfluorescently-labeled antibodies that specifically bind to BCRP (panelA), CD133 (panel B), Notch 1 (panel C), and Notch 2 (panel D). Antibodystaining was determined by immunofluorescence microscopy, and thepercentage of positive cells in each population was quantitated (panelsE-H).

FIG. 10A-10D illustrates the results of a screen for anti-cancer stemcell activity using the MCF-7 cancer cell line. MCF-7 cells wereincubated with 1 uM gamma secretase inhibitor (Calbiochem, San Diego,catalog number 565750) for 7 days (B, D). Control cells were culturedwithout a gamma secretase inhibitor (A, C). Following drug treatment,cells were washed, and then the SP was analyzed as described herein, inthe presence (C, D) or absence (A, B) of 10 uM reserpine. The percentageof SP cells in the culture is given for each experimental condition.

DETAILED DESCRIPTION

The present invention is directed, at least in part, to the use ofcancer cell lines, commercially available or otherwise, for theidentification and isolation of SP cells containing cancer stem cells.As used herein, the term “side population” or “SP” refers to a subset ofcells isolated from or identified within a larger cell population, e.g.,a cancer cell line, which contains cancer stem cells. Accordingly,cancer stem cells obtained from a cancer cell line are termed “cellline-derived cancer stem cells.”

In another aspect, the invention provides methods for identifying cancerstem cell markers. In still another aspect, the present inventionincludes screening methods, including high throughput screening methods,utilizing cell line-derived cancer stem cells, to identify anti-cancercompounds as well as subsequent testing of such identified candidatecompounds for anti-cancer activity. In yet another aspect, the inventionprovides methods for the treatment of cancer in a subject comprisingadministering an anti-cancer compound identified by the methodsdescribed herein. Furthermore, the invention provides methods forculturing cancer stem cells.

In the methods of the invention, there is often a comparison of a cellline-derived cancer stem cell with a non-cancer stem cell. Non-cancerstem cells include the cancer cell line from which the cell line-derivedcancer stem cell was obtained and primary bulk tumor cells (cancercells) of the same type of cancer as the cancer cell line. For example,and not by way of limitation, in the case of cell line-derived cancerstem cells from the MCF-7 human breast cancer cell line, the non-cancerstem cell can either be bulk MCF-7 cells or primary breast cancer cells.Similarly, in the case of a cell line-derived cancer stem cell from theU-20S or SaOS-2 cancer cell line, bulk tumor cells from that line orfrom a primary osteosarcoma would be non-cancer stern cells.

One aspect of the invention provides a method of identifying and/orobtaining a cell line-derived cancer stem cell comprising;

-   -   providing a population of cancer cells from a cultured cancer        cell line, and;    -   determining the presence of a stem cell marker in one or more        cells in the population,    -   the presence of the marker being indicative that the one or more        cells are cell line-derived cancer stem cells.

In one embodiment, cultured cancer cells are cells from establishedcancer cell lines that have undergone numerous passages in vitro.

Cancer cell lines are initially derived from cancerous tissue, forexample primary or metastatic tumours, but have been maintained in aculture for an extended period. Such cells can be reproducedindefinitely in vitro (i.e., they are continuous cell lines) and have apotentially unlimited lifespan in culture.

Cultured cancer cell lines generally consist of a single cell type andare distinct from primary cell cultures, which generally consist of amixed population of cell types, many of which will only survive for oneor a few passages before dying.

Many cancer cell lines suitable for use in the present methods areknown, including adenocarcinoma cell lines such as HeLa, prostate cancercell lines, lung cancer cell lines, gastrointestinal cancer cell lines,bowel cancer cell lines, colon cancer cell lines, breast carcinoma celllines such as MCF7, ovarian carcinoma cell lines, testicular cancer celllines, glioma cell lines such as C6, liver cancer cell lines, kidneycancer cell lines, bladder cancer cell lines, pancreatic cancer celllines, brain cancer cell lines, neuroblastoma cell lines such as B104,sarcoma cell lines, osteosarcoma cell lines, melanoma cell lines,lymphoma cell lines, retinoblastoma cell lines, skin cancer cell lines,leukemia cell lines, and lymphoma cell lines.

A wide range of suitable cancer cell lines are available from commercialsources, including European Collection of Cell Cultures (ECCC;Salisbury, UK), American Type Culture Collection (ATCC; Manassas, USA),Coriell Institute for Medical Research (USA), Riken Bioresource Center(Japan), and Japanese Collection of Research Bioresources (Japan).

In one embodiment, the cultured cancer cells are human cancer cells.

In some embodiments, cultured cancer cells exclude osteosarcoma cells.

A cell line-derived cancer stem cell is a member of a sub-population ofcells within the population of cultured cancer cells that possesses oneor more stem cell properties, e.g., the expression of a stem cellmarker.

A cancer stem cell is able to generate both cancer stem cells andnon-stem cells in culture (unlike other cells in the population) and canalso generate cells of different lineages both in vitro and in vivo.Furthermore, cancer stem cells are shown herein to be largelyresponsible for in vivo malignancy. A cell line-derived cancer stem cellis similarly able to generate both cancer stem cells and non-stem cellsin culture. As exemplified herein, a cell line-derived cancer stem cellcan also establish a tumor in vivo.

Cancer stern cell markers suitable for use in the present methodsinclude any marker whose expression is increased or decreased in acancer stem cell relative to a non-cancer stem cell. Cancer stem cellmarkers suitable for use in the present methods also include any markerwhose expression is increased or decreased in a cancer stem cellrelative to vital normal (non-neoplastic) stem cells and/or tissues.

Many stem cell markers are known in the art, including, for example stemcell factor, (SCF or c-Kit ligand), telomerase, TRA-1-60, TRA-1-81,vimentin, genesis, germ cell nuclear factor, hepatocyte nuclearfactor-HNF-4, nestin, breast cancer resistance protein (BCRP), NG2,A2B5, polysialylated form of neuronal cell-adhesion molecule (PSA-NCAM),nucleostemin, sox-2, musashi-1 and -2, hairy and enhancer-of-splits(Hes-1, -3, -5), melk, PSP, Inhibitor of differentiation (Id-1, -2, -3,-4), Bmi-1, brca-1, Oct-4, Nanog, FGF-4, Pax6, Stage-specific embryonicantigens (SSEA-1,-3,-4), Cluster designation 30 (CD30), CD34, CD44,Notch, CD123, CD133, CD24, Cripto (TDGF-1) ATA-4 gene, GCTM-2, Alkalinephosphatase, Alpha-fetoprotein (AFP), Bone morphogenetic protein-4,mdr-1, hiwi, prominin-1 and Brachyury. Also, certain signaling pathwaysand the proteins that make up these signaling pathways have beenassociated with stern cell biology and renewal of stem cells. Theseinclude the Wnt, Notch, and Hedgehog pathways. Molecules involved inthese pathways, including, but not limited to Wnt1, Wnt10, Wnt11, Notch1, Notch 2, Notch 3, and Notch 4, are also included as stem cell markersas defined herein.

The Notch family of receptors has been implicated in stem celldevelopment and differentiation (see, Morrison et al., Cell 101(5):499-510 (2000); Artavanis-Tsakonas et al., Science 284: 770 (1999); andArtavanis-Tsakonas et al., Science 268: 225-232 (1995); U.S. Pat. No.6,090,922, incorporated by reference). There are four known mammalianNotch family members. Notch 4 is the human ortholog of the mouse int-3oncogene that plays a role in breast cancer in mice. Gallahan et al.,Cancer Res. 56(8): 1775-85 (1996); Uyttendaele et al., Development 2122:251 (1996); Imatani & Callahan, Oncogene 19(2): 223-31 (2000),incorporated herein by reference). Molecules involved in the Wnt pathwayare described in U.S. Pat. No. 6,159,462, the contents of which areincorporated herein by reference. Hedgehog pathway-related molecules aredescribed in U.S. Pat. No. 6,291,516, the contents of which areincorporated by reference.

Certain differentiation markers have also been associated with stemcells as well, including integrin alpha-6, mucin-1 (EMA), estrogenreceptor-alpha, estrogen receptor-beta, cytokeratin-14, cytokeratin-18,and cytokeratin 19, and are also included as stem cell markers.

For example, CD34 has been used to isolate leukaemic stem cells ((Wulf,G. G. et al. (2001) supra)) and both CD24 and CD44 have been used toisolate breast cancer stein cells (Al-Hajj, M. et al (2003) supra).

In some embodiments, the marker may be a verapamil or reserpinesensitive ATP-binding cassette (ABC) transporter. The ABC transporterBCRP (Gottesman et al (2002) Nat. Rev. Cancer 2, 48-58; Zhou, S. et al.(2001) Nat. Med. 7, 1028-1034; Zhou, S. et al (2002) Proc. Natl. Acad.Sci. USA 99, 12339-12344; Bunting, K. D. (2002) Stem Cells (Dayton) 20,11-20) is shown herein to be a useful stem cell marker. The sequence ofmouse bcrp has the Genbank accession numbers BC053730 and AF140218, thesequence of human bcrp has the Genbank accession numbers AB056867,AY017168, and BC021281, and the sequence of RAT bcrp has the Genbankaccession number AB094089.

The presence of a cancer stem cell marker on a cell may be determined byany convenient method.

In some embodiments, the expression of a marker may be determined at thepolypeptide level, by determining the presence or level of a stein cellmarker polypeptide in or on the surface of the cell. For example, thebinding of a cultured cancer cell to an antibody that binds specificallyto stem cell marker may be determined. Many techniques and methodologiesfor determining the binding of antibodies to cell antigens are known inthe art. Suitable methodologies include fluorescence activated cellsorting (FACS), immunohistochemical staining, immunocytochemicalstaining, Western Blotting, immunofluorescence, enzyme linkedimmunosorbent assays (ELISA), radioimmunoassays (RIA), immunoradiometricassays (IRMA) and immunoenzymatic assays (IEMA), including sandwichassays using monoclonal and/or polyclonal antibodies. All of theseapproaches are well known in the art. For example, in one embodiment ofthe invention, antibodies specific for BCRP, Notch, or CD133 may be usedto specifically identify cell line-derived cancer stem cells in thebreast cancer cell line, MCF-7. For example, in one embodiment, theseantibodies are incubated with cultures of MCF-7 cells and the cells areseparated to identify the cell line-derived cancer stem cellsub-population by flow cytometry.

In some embodiments, the expression of a marker may be determined at thenucleic acid level, by determining the expression of a nucleic acid, forexample mRNA, encoding a cancer stem cell marker. Many suitabletechniques are available, for example Northern blot, RNAse protection,RT-PCR, real-time PCR, microarrays, and serial analysis of genetranscription (SAGE). For example, in one embodiment of the invention,cell line-derived cancer stein cells are isolated from the human breastcancer cell line, MCF-7, e.g., by flow cytometry using fluorescentHoechst dye exclusion or fluorescent antibodies to a cancer stem cellmarker, e.g., BCRP, Notch, or CD133. Gene expression analysis of certaincandidate genes can then be performed by RT-PCR on these isolated cellline-derived cancer stem cells. In this example, the non-cancer stemcell population (whether cell line cells or primary tumor cells from thesame type of tumor) may be used as a control. This analysis willelucidate gene products that are differentially expressed in cancer stemcells. The method of gene expression analysis by RT-PCR is widelyavailable to one skilled in the art.

In some embodiments, the presence of a stem cell marker may bedetermined using a functional assay. The presence of a verapamil orreserpine sensitive ABC marker may be determined, for example, bycontacting the cells with a fluorescent dye and determining theexpulsion of dye from the cell. In particular, the expulsion of dye inthe presence and absence of verapamil or reserpine may be determined.Suitable fluorescent dyes include Hoechst 33342. Other suitable dyesinclude Rhodamine 123.

Cells that expel fluorescent dye, in particular in the absence relativeto the presence of verapamil or reserpine, may be identified asexpressing a verapamil or reserpine sensitive ABC marker and maytherefore be candidate cancer stem cells.

The expulsion of fluorescent dye by a cell may be determined by anyconvenient method, including fluorescence activated cell sorting (FACS).

A cultured cell identified as expressing a cancer stem cell marker maybe isolated and/or purified from the cultured cell population. Anyconvenient method may be used. In some embodiments, methods which allowthe identification of the marker and the isolation of the expressingcell in a continuous process may be employed. Suitable methods includefluorescence activating cell sorting (FACS).

In other embodiments, cell line-derived cancer stein cells may beisolated and/or purified from the cultured cell population usingantibodies which bind specifically to stem cell markers. Suitablemarkers include CD133, BCRP, Notch 1, Notch 2, and CD34. Suitablemethods include conventional affinity column chromatography and/ormagnetic bead separation.

In other embodiments, cell line-derived cancer stem cells may beisolated and/or purified from the cultured cell population usingnegative selection using an antibody which binds to cancerous non-stemcells but does not bind to cancer stem cells. For example, CD138 hasbeen shown to be present on the bulk but not the cancer stem cellpopulation of multiple myeloma (Matsui, W., et al (2004) Blood 103,2332-2336).

Cell line-derived cancer stem cells isolated and/or purified asdescribed herein may be analysed (e.g., for gene expression) de novo ormay be maintained and/or cultured in vitro. Suitable methods andreagents for maintaining cells in culture are well known in the art. Forexample, a standard medium, such as Dulbeccos Modified Eagle Medium(DMEM) supplemented with 10% fetal calf serum (FCS), 100 units/mlpenicillin G, and 100 μg/ml streptomycin may be used.

In one embodiment, cells may be suspended or immersed in a serum freemedium that comprises basic fibroblast growth factor (bFGF) andplatelet-derived growth factor (PDGF), for example at 5 to 100 ng/ml,e.g., about 5 ng/ml, 10 ng/ml, 20 ng/ml, 30 ng/ml, 40 ng/ml, 50 ng/ml,60 ng/ml, 70 ng/ml, 80 ng/ml, 90 ng/ml or 100 ng/ml. Cells may then becultured using conventional techniques.

Cell line-derived cancer stem cells identified and/or obtained using thepresent methods are useful for a wide range of applications, for examplefor the development of cancer therapies. In particular, cells may beuseful in the production of antibodies that bind to cell line-derivedcancer stern cells and to identify cancer stem cell-associated antigensand markers.

In some embodiments, cancer stem cell-associated antigens and markersmay be identified at the nucleic acid level.

For example, in one embodiment, a method of identifying a cancer stemcell-associated nucleic acid molecule comprises;

-   -   comparing the expression of one or more nucleic acid molecules        in a cell line-derived cancer stem cell obtained from a        population of cultured cancer cells by a method described herein        with the expression of the one or more nucleic acid molecules in        a non-stem cell, and;    -   identifying a nucleic acid molecule whose expression is        modulated, e.g., increased or decreased in the cell line-derived        cancer stem cell relative to the non-stem cell as a cancer stem        cell-associated nucleic acid molecule.

In some embodiments, a method of identifying a cancer stemcell-associated nucleic acid molecule comprises;

-   -   comparing the expression of one or more nucleic acid molecules        in a cancer stem cell obtained from a population of cultured        cancer cells by a method described herein with the expression of        the one or more nucleic acid molecules in a normal        (non-neoplastic) stem cell and/or tissue, and;    -   identifying a nucleic acid molecule whose expression is        modulated, e.g., increased or decreased in the cell line-derived        cancer stem cell relative to the normal (non-neoplastic) stem        cell and/or tissue as a cancer stem cell-associated nucleic acid        molecule.

The stem cell-associated nucleic acid molecule may be cloned andexpressed to produce a recombinant stem cell-associated polypeptide.

A test compound, for example an inhibitory polynucleotide, includingantisense or double-stranded RNA (RNA interference) or an inhibitorymolecule such as an aptamer, may be screened for ability to block thecancer stem cell-associated nucleic acid and/or to impair cellline-derived cancer stem cell growth and/or viability.

Methods for the cloning and expression of nucleic acids to producerecombinant polypeptides are well known in the art.

In some embodiments, cancer stem cell-associated antigens and markersmay be identified at the polypeptide level.

For example, in one embodiment, a method of identifying a cancer sterncell-associated polypeptide comprises;

-   -   comparing the level or amount of one or more polypeptides in a        cell line-derived cancer stem cell obtained from a population of        cultured cancer cells by a method described herein with the        level or amount of the one or more polypeptides in a non-stein        cell, and;    -   identifying a polypeptide from the one or more polypeptides        whose level or amount is modulated, e.g., increased or decreased        in the cell line-derived cancer stem cell relative to the        non-stem cell as a cancer stem cell-associated polypeptide.

In some embodiments, a method of identifying a cancer stemcell-associated polypeptide comprises;

-   -   comparing the level or amount of one or more polypeptides in a        cell line-derived cancer stem cell obtained from a population of        cultured cancer cells by a method described herein with the        level or amount of the one or more polypeptides in a normal        (non-neoplastic) stem cell and/or tissue, and;    -   identifying a polypeptide whose expression is modulated, e.g.,        increased in the cell line-derived cancer stem cell relative to        the normal (non-neoplastic) stem cell and/or tissue as a cancer        stem cell-associated polypeptide.

The stem cell-associated polypeptide may be isolated and/or purified. Anisolated polypeptide may be investigated further. For example, it may besequenced using methods well-known in the art.

Cancer stem cell-associated polypeptides may be useful for example inthe production of cancer stem cell-specific antibodies. These antibodiesmay be useful in a range of applications, including cancer therapy, andare discussed in more detail below.

The present invention also includes high-throughput methods foridentifying cancer stem cell markers. For example, cell line-derivedcancer stem cells may be tested for the expression of any of a panel ofcandidate gene products by, for example, RT-PCR using methods that arewidely available to one skilled in the art. Non-cancer stem cells, ornormal stem cells may be used as control cells.

Other aspects of the invention relate to methods of expanding asub-population of cancer-stem cells isolated from a cancer cell line.

In one embodiment, a method of culturing a cancer stem cell,particularly a cell line-derived cancer stem cell, comprises;

-   -   suspending the cell in a serum-free medium comprising PDGF and        bFGF, and;    -   causing or allowing the cell to proliferate in the medium.

Suitable serum free media are well-known in the art. For example,Dulbeccos Modified Eagle Medium supplemented with 10 μg/ml bovineinsulin, 100 μg/ml human transferrin, 100 μg/ml BSA, 60 ng/mlprogesterone, 16 μg/ml putrescine, 40 ng/ml sodium selenite, 63 μg/ml,N-acetylcysteine, 5 μM forskolin, 50 units/ml penicillin, and 50 μg/mlstreptomycin, as well as 10 ng/ml bFGF and 10 ng/ml PDGF may be used.

Cells may, for example, be maintained in a suitable culture vessel atabout 37° C. in a humidified 5% CO₂/95% air atmosphere.

A medium suitable for the expansion or maintenance of a cancer stemcell, and particularly a cell line-derived cancer stem cell, populationmay be produced by providing a serum free growth medium, andsupplementing the medium with PDGF and bFGF.

PDGF and bFGF cytokines may be mammalian, more preferably human and maybe conveniently obtained from commercial suppliers (e.g., PeproTech(Rocky Hill, N.J.)).

Suitable concentrations of PDGF and bFGF in the medium are about 5 to100 ng/ml, e.g., about 5 ng/ml, 10 ng/ml, 20 ng/ml, 30 ng/ml, 40 ng/ml,50 ng/ml, 60 ng/ml, 70 ng/ml, 80 ng/ml, 90 ng/ml or 100 ng/ml.

Cancer stem cells are shown herein to be play a significant role in themalignancy of cancer conditions. Therefore, compounds that specificallytarget these cells may be useful as anti-cancer therapeutics.Accordingly, the present invention also includes the use of cancer stemcell-specific antibodies and cell line-derived cancer stem cells, e.g.,cell line-derived cancer stem cells identified from cancer cell lines,as described herein, to screen test compounds to identify candidatecompounds having anti-cancer stem cell activity. The screening of testcompounds for anti-cancer stem cell activity overcomes many of thelimitations associated with classic drug screening, which testscompounds only for activity against the entire cell line (i.e., with nocell line-derived cancer stem cell readout). Also, cell line-derivedcancer stem cells identified in cancer cell lines can be used assurrogates for the study of cancer stem cells from primary humantissues. The use of cell lines overcomes many of the limitationsassociated with testing drugs using primary tissue since primary cancertissue is of finite supply for a given experiment. Accessing additionalprimary tissues interrupts the reproducibility of an experiment which isnot the case when cell lines are used. In addition, primary tissues,since finite, cannot be immortally transfected with promoter-reporterconstructs in the way cell lines can. Also, cancer cell lines provide avirtually unlimited source of cells that behave as cancer stem cells,enabling the screening of large numbers of compounds in a singleexperiment, and reproducibly so. The ability of cancer cell lines to bescaled-up as needed enables the testing of large compound libraries(high throughput screens).

A “test compound” is a molecule that can be tested for its ability toact as a modulator of the growth, proliferation, viability, and/ordifferentiation status of a cancer stern cell, its ability to act as amodulator of a gene or gene product expression or activity, or itsability to bind to a cancer stem cell. Test compounds can be selectedwithout limitation from small inorganic and organic molecules (i.e.,those molecules of less than about 2 kD, and more preferably less thanabout 1 kD in molecular weight), polypeptides (including native ligands,antibodies, antibody fragments, and other immunospecific molecules),oligonucleotides and polynucleotide molecules, e.g., antisense andinterfering RNA, and derivatives thereof. A compound that modulates thegrowth, proliferation, viability, and/or differentiation status of acell line-derived cancer stem cell, binds to a cell line-derived cancerstem cell, or modulates the expression or activity of a nucleic acid orprotein expressed by a cell line-derived cancer stem cell is designatedherein as a “candidate compound” or “lead compound” suitable for furthertesting and development.

Suitable test compounds include compounds identified as binding to cellline-derived cancer stem cells using methods described herein. In oneembodiment of the invention, a cancer cell line is treated with a gammasecretase inhibitor, and the effect on the cell line-derived cancer stemcell population is then monitored by flow cytometry using Hoechst dyeexclusion or using an antibody that specifically binds to cellline-derived cancer stem cells in combination with a marker forapoptosis (e.g., Annexin, or Propidium Iodide).

The test compounds of the present invention can be obtained using any ofthe numerous approaches in combinatorial library methods known in theart, including: biological libraries; spatially addressable parallelsolid phase or solution phase libraries; synthetic library methodsrequiring deconvolution; the ‘one-bead one-compound’ library method; andsynthetic library methods using affinity chromatography selection. Thebiological library approach is limited to peptide libraries, while theother four approaches are applicable to peptide, non-peptide oligomer orsmall molecule libraries of compounds (Lam, K. S. (1997) Anticancer DrugDes. 12:145).

Examples of methods for the synthesis of molecular libraries can befound in the art, for example in: DeWitt et al. (1993) Proc. Natl. Acad.Sci. U.S.A. 90:6909; Erb et al. (1994) Proc. Natl. Acad. Sci. USA91:11422; Zuckermann et al. (1994). J. Med. Chem. 37:2678; Cho et al.(1993) Science 261:1303; Carrell et al. (1994) Angew. Chem. Int. Ed.Engl. 33:2059; Carell et al. (1994) Angew. Chem. Tnt. Ed. Engl. 33:2061;and in Gallop et al. (1994) J. Med. Chem. 37:1233.

Libraries of compounds may be presented in solution (e.g., Houghten(1992) Biotechniques 13:412-421), or on beads (Lam (1991) Nature354:82-84), chips (Fodor (1993) Nature 364:555-556), bacteria (LadnerU.S. Pat. No. 5,223,409), spores (Ladner U.S. Pat. No. '409), plasmids(Cull et al. (1992) Proc. Natl. Acad. Sci. USA 89:1865-1869) or on phage(Scott and Smith (1990) Science 249:386-390); (Devlin (1990) Science249:404-406); (Cwirla et al. (1990) Proc. Natl. Acad. Sci.87:6378-6382); (Felici (1991) J. Mol. Biol. 222:301-310); (Ladnersupra.).

One embodiment of the present invention includes the use of cancer celllines as a source of cancer stem cells for use in such screens,including high throughput screens.

The invention also includes the use of cancer stem cell-specificantibodies to monitor the growth, proliferation, and/or viability of thecell line-derived cancer stem cell population of cancer cell lines foruse in drug screens and the development of assays for drug screens,including high throughput screens.

Another aspect of the invention provides a method of identifying and/orobtaining an anti-cancer compound comprising:

-   -   contacting a cell isolated by a method described herein with a        test compound, and;    -   determining binding of the compound to the cell.

Binding may be determined relative to binding to a non-stern cell, forexample a cancer cell or a normal non-cancer cell, or a normal sterncell.

An increase in binding to a cell line-derived cancer stem cell relativeto a non-stem cell may be indicative that the compound is an anti-cancercompound.

Binding of a compound to a cell may be determined using any one ofnumerous methodologies known in the art.

Alternatively and/or additionally to detecting or measuring binding, theeffect of a test compound on the growth and/or proliferation of a cellline-derived cancer stem cell may be determined.

A method of identifying and/or obtaining an anti-cancer compoundcomprises

-   -   contacting a cell isolated by a method described herein with a        test compound, and;    -   determining the growth, proliferation, viability, and/or        differentiation status of the cell in the presence of the        compound.

The growth, proliferation, viability, and/or differentiation status ofthe cell may be determined relative to binding to a non-stem cell, forexample a cancer cell or a normal non-cancer cell, or a normal stemcell.

A decrease in the growth, proliferation, and/or viability or a change inthe differentiation status of the cell in the presence relative to theabsence of test compound is indicative that the test compound is acandidate compound for the treatment of a cancer condition.

Growth, proliferation, viability, and/or differentiation status may bedetermined using any convenient technique.

Another method of identifying and/or obtaining an anti-cancer compoundcomprises

-   -   contacting a cell isolated by a method described herein with a        test compound, and;    -   determining the modulation in expression or activity of a cancer        stem cell marker in the presence of the compound as compared to        the expression or activity of the cancer stem cell marker in the        absence of the compound.

Another method of identifying and/or obtaining an anti-cancer compoundcomprises

-   -   contacting a cell isolated by a method described herein with a        test compound, and;    -   a change in the morphology of the cell line-derived cancer stem        cell in the presence of the test compound.

In another embodiment, the cell line-derived cancer stern cells aremonitored in the presence of a test compound, e.g., via fluorescentantibody- or promoter-based reporters, to identify compounds withanti-cancer stern cell activity.

In yet another embodiment of the invention, high throughput screening oftest compounds comprises synthesis of large numbers of different testcompounds, e.g., a library of test compounds. Several methods ofautomated assays that have been developed in recent years enable thescreening of tens of thousands of compounds in a short period of time(see, e.g., U.S. Pat. Nos. 5,585,277, 5,679,582, and 6,020,141,incorporated herein by reference). In one embodiment, the test compoundsmay be linked to a solid substrate. In another embodiment, the testcompounds are contacted with cell line-derived cancer stem cells, ormolecules isolated from such cells. Cell line-derived cancer stem cellsthat are bound to one or more test compounds are then detected bymethods well known in the art. In one embodiment, automated methods maybe used to identify compounds that bind to cancer stern cells.

In another embodiment, a high throughput assay of the inventioncomprises measuring a response of the target cells (cell line-derivedcancer stem cells) that provides detectable evidence that the testcompound may have anti-cancer stem cell activity. For example, aresponse includes binding to a test compound, modulation in the growth,proliferation, viability, and/or differentiation status of the cellline-derived cancer stem cell, modulation in expression or activity of acancer stem cell marker, or changes in morphology of the cellline-derived cancer stem cell. A detectable signal is compared tocontrol cells. Techniques such as differential display, representationaldifference analysis (RDA), GEM-Gene Expression Microarrays (U.S. Pat.No. 5,545,531), suppressive subtraction hybridization (SSH) and directsequencing (PCT patent application WO 96/17957) can be used in the highthroughput screening methods of the invention. In one embodiment of theinvention, cell line-derived cancer stem cells are not isolated from thecell line, but rather are maintained within the cell line and labeledwith an antibody or a promoter-reporter, the expression of which ispreferentially expressesd by the cancer stem cells. In this way, thisassay can be used to screen compounds (e.g., in a high throughputscreen) for activity against cancer stem cells. One example of thismethod comprises the use of this assay in combination with markers ofcell death, proliferation, or differentiation (e.g. Annexin, propidiumiodide, etc) to identify compounds that affect cancer stem cells. In oneembodiment, compounds that affect cancer stem cells may be identifiedusing flow cytometry. In another embodiment, compounds that affectcancer stern cells may be identified using methods other than flowcytometry, such as fluorimetry.

Appropriate control experiments may be performed in accordance withappropriate knowledge and practice of the ordinary skilled person.

Antibody molecules are one class of test compounds suitable forscreening as anti-cancer agents.

An antibody molecule includes any binding substance having animmunoglobulin-binding domain with the required specificity, includingmodified and unmodified antibodies, antibody fragments and derivatives.

Exemplary antibody fragments which are capable of binding an antigen orother binding partner are the Fab fragment consisting of the VL, VH, Cland CH1 domains; the Fd fragment consisting of the VH and CH1 domains;the Fv fragment consisting of the VL and VH domains of a single arm ofan antibody; the dAb fragment which consists of a VH domain; isolatedCDR regions and F(ab′)2 fragments, a bivalent fragment including two Fabfragments linked by a disulphide bridge at the hinge region. Singlechain Fv fragments are also included.

An antibody molecule may be identified and/or obtained which bindsspecifically to cancer stem cells. In other words, an antibody moleculemay bind preferentially to stem cells relative to non-stem cells withina population of cultured cancer cells. In some embodiments, antibodymolecules may bind preferentially to cell line-derived cancer stem cellswithin the population of cultured cancer cells relative to non-cancercells from the organism from which the cultured cells were derived.

Preferential or specific binding of an antibody molecule ischaracterised by a binding affinity for a target antigen, such as acancer stem cell antigen, that is substantially higher than its bindingaffinity to other antigens, including antigens expressed by cells whichare not cancer stem cells. For example, an antibody may bind to thetarget antigen with at least 5 fold, at least 10 fold, at least 20 fold,or at least 100 fold greater affinity than other non-target antigens.

Preferably, an antibody molecule shows little or no binding tonon-cancer cells, in particular little or no binding to non-cancer cellsfrom the organism from which the cultured cells were derived.

The reactivity of an antibody molecule with a target antigen may bedetermined in methods of the invention by any appropriate means.Suitable protocols are well known in the art (see for exampleAntibodies: A Laboratory Manual E. Harlow and D. Lane, Cold SpringHarbor Laboratory Press, N Y, 1988). Tagging with individual reportermolecules is one possibility. The reporter molecules may directly orindirectly generate detectable, and preferably measurable, signals. Thelinkage of reporter molecules may be directly or indirectly, covalently,e.g., via a peptide bond or non-covalently. Linkage via a peptide bondmay be as a result of recombinant expression of a gene fusion encodingantibody and reporter molecule. The actual mode of determining thebinding of an antibody molecule is not a feature of the invention andthose skilled in the art are able to choose a suitable mode according totheir preference and general knowledge.

Antibody molecules for use in the present methods may be produced usingmethods which are standard in the art. Methods of producing antibodiesinclude immunising a mammal (e.g., mouse, rat, rabbit, horse, goat,sheep or monkey) with a cell line-derived cancer stem cell or a cancerstem cell antigen, e.g., identified in a cell line-derived cancer stemcell. Antibodies may be obtained from immunised animals using any of avariety of techniques known in the art, and screened, preferably usingbinding of antibody to antigen of interest. For instance, Westernblotting techniques or immunoprecipitation may be used (Armitage et al.,1992, Nature 357: 80-82). Isolation of antibodies and/orantibody-producing cells from an animal may be accompanied by a step ofsacrificing the animal.

A method of producing an antibody molecule which binds to a cancer stemcell comprises;

-   -   introducing a cell line-derived cancer stem cell or a cancer        stem cell antigen obtained by a method described above to a test        animal;    -   removing a sample of serum from the animal and,    -   identifying one or more antibody molecules in the sample which        bind to the cell line-derived cancer stem cell or antigen.

In some embodiments, cells may be fixed by 4% paraformaldehyde and thenused for immunization in order to generate antibodies specific forcell-surface molecules.

The preferential or specific binding of one or more antibody moleculesin the sample to a cell line-derived cancer stem cell relative to othercell types may be determined.

As an alternative or supplement to immunising a mammal with a cell,polypeptide or peptide, an antibody specific for a cell line-derivedcancer stem cell or cancer stem cell antigen may be obtained from arecombinantly produced library of expressed immunoglobulin variabledomains, e.g., using lambda bacteriophage or filamentous bacteriophagewhich display functional immunoglobulin binding domains on theirsurfaces; for instance see WO92/01047. The library may be naive, that isconstructed from sequences obtained from an organism which has not beenimmunised with any of the proteins (or fragments), or may be oneconstructed using sequences obtained from an organism which has beenexposed to the antigen of interest.

A method of producing an antibody molecule which binds to a cancer stemcell comprises;

-   -   contacting a population of antibody molecules with a cell        line-derived cancer stem cell obtained by a method described        herein and;    -   identifying one or more antibody molecules in the population        which bind to the cell line-derived cancer stern cell.

The preferential or specific binding of one or more antibody moleculesin the population to a cancer stem cell relative to other cell types maybe determined.

A further aspect of the invention provides an antibody molecule producedby a method described herein.

Other test compounds for use in methods of the invention may be naturalor synthetic chemical compounds used in drug screening programmes.Extracts of plants which contain several characterised oruncharacterised components may also be used. Combinatorial librarytechnology (Schultz, JS (1996) Biotechnol. Prog. 12:729-743) provides anefficient way of testing a potentially vast number of differentsubstances for ability to modulate the activity of a polypeptide.

The amount of test substance or compound which may be added willnormally be determined by trial and error depending upon the type ofcompound used.

Typically, from about 0.0001 to 10 mM concentrations of putativeinhibitor compound may be used, for example from 1 to 100 μM.

A method as described herein may comprise the step of identifying a testcompound as a compound having anti-cancer stem cell activity, e.g., acompound which affects the cancer stem cell growth, proliferation,viability, and/or differentiation status, modulates expression oractivity of a cancer stem cell marker, which is therefore a candidateanti-cancer compound.

Following identification of a compound having anti-cancer stem cellactivity, e.g., a compound which affects cell line-derived cancer stemcell growth, proliferation, viability, and/or differentiation status ormodulates expression or activity of a cancer stem cell marker, thecompound may be investigated further, in particular for its ability toreduce or inhibit the progression of a cancer condition in an animal orindividual.

The test compound may be isolated and/or purified or alternatively itmay be synthesised using conventional techniques of recombinantexpression or chemical synthesis. Furthermore, it may be manufacturedand/or used in preparation, i.e. manufacture or formulation, of acomposition such as a medicament, pharmaceutical composition or drug.These may be administered to individuals for the treatment of cancerconditions as described below. Methods of the invention thus compriseformulating the test compound in a pharmaceutical composition with apharmaceutically acceptable excipient, vehicle or carrier fortherapeutic application, as discussed further below.

One example of such a compound is a gamma secretase inhibitor, which maybe tested for activity against cell line-derived cancer stem cellswithin, or isolated from, cancer cell lines using methods that areavailable to one skilled in the art. Therefore, one embodiment of theinvention is the evaluation of a gamma secretase inhibitor foranti-cancer activity by treating a cancer cell line with a gammasecretase inhibitor and specifically monitoring the effect on cellline-derived cancer stem cells (e.g., growth, cell death,anti-proliferation, differentiation status, etc.). This is accomplishedusing, for example, flow cytometry based on Hoechst dye exclusion, orusing an antibody that specifically binds to the cell line-derivedcancer stem cell population in combination with an apoptosis marker(e.g., Annexin, or Propidium Iodide).

Following identification of a compound, such as an antibody molecule,which inhibits the growth of cell line-derived cancer stem cells asdescribed above, a method further comprises modifying the compound tooptimise the pharmaceutical properties thereof. This modification mayinclude conjugating the compound to a toxin, drug, prodrug, orradioisotope.

Further optimisation or modification can then be carried out to arriveat one or more final compounds for in vivo or clinical testing.

A compound which inhibits cancer stern cell growth, proliferation,and/or viability, or modulates cancer stem cell differentiation statusor modulates the expression or activity of a cancer stem cell marker, asdescribed above, may be formulated in a composition. A composition mayinclude, in addition to the compound, a pharmaceutically acceptableexcipient, carrier, buffer, stabiliser or one or more other materialswell known to those skilled in the art. Such materials should benon-toxic and should not interfere with the efficacy of the activeingredient. The precise nature of the carrier or other material maydepend on the route of administration, e.g., oral, intravenous,cutaneous or subcutaneous, nasal, intramuscular, topical orintraperitoneal routes.

Pharmaceutical compositions for oral administration may be in tablet,capsule, powder or liquid form A tablet may include a solid carrier suchas gelatin or an adjuvant. Liquid pharmaceutical compositions generallyinclude a liquid carrier such as water, petroleum, animal or vegetableoils, mineral oil or synthetic oil. Physiological saline solution,dextrose or other saccharide solution or glycols such as ethyleneglycol, propylene glycol or polyethylene glycol may be included.

For intravenous, cutaneous or subcutaneous injection, or injection at aparticular site of affliction, the active ingredient will be in the formof a parenterally acceptable aqueous solution which is pyrogen-free andhas suitable pH, isotonicity and stability. Those of relevant skill inthe art are well able to prepare suitable solutions using, for example,isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection,Lactated Ringer's Injection. Preservatives, stabilisers, buffers,antioxidants and/or other additives may be included, as required.

Another aspect of the invention provides a method of treatment of acancer condition comprising;

-   -   administering a test compound identified as described herein,        for example an antibody molecule which binds to a cancer stern        cell, to an individual in need thereof

A cancer condition may include lung cancer, gastrointestinal cancer,bowel cancer, colon cancer, breast carcinoma, ovarian carcinoma,prostate cancer, testicular cancer, liver cancer, kidney cancer, bladdercancer, pancreatic cancer, brain cancer, sarcoma, osteosarcoma, Kaposi'ssarcoma, melanoma, lymphoma, retinoblastoma or leukaemia.

Administration is preferably in a “prophylactically effective amount” ora “therapeutically effective amount” (as the case may be, althoughprophylaxis may be considered therapy), this being sufficient to showbenefit to the individual. The actual amount administered, and rate andtime-course of administration, will depend on the nature and severity ofwhat is being treated. Prescription of treatment, e.g., decisions ondosage etc., is within the responsibility of general practitioners andother medical doctors, and typically takes account of the disorder to betreated, the condition of the individual patient, the site of delivery,the method of administration and other factors known to practitioners.Examples of the techniques and protocols mentioned above can be found inRemington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed), 1980.

Certain aspects and embodiments of the invention will now be illustratedby way of example and with reference to the accompanying Figures.

EXAMPLES

Materials and Methods

Chemicals.

Chemicals were purchased from Sigma unless otherwise indicated.Recombinant cytokines were purchased from PeproTech (Rocky Hill, N.J.)unless otherwise indicated.

Cell Culture

Various cancer cell lines were studied, including the rat glioma lineC6, the human breast cancer line MCF-7, the human osteosarcoma linesU-20S and SaOS-2, the rat neuroblastomaline B104, and the humanadenocarcinoma line HeLa.

The cells were cultured in DMEM, supplemented with 10% FCS, 100 units/mlpenicillin G, and 100 μg/ml streptomycin (GIBCO). In some experiments,C6 cells were cultured in serum-free DMEM containing 10 μg/ml bovineinsulin, 100 μg/ml human transferrin, 100 pg/ml BSA, 60 ng/mlprogesterone, 16 μg/ml putrescine, 40 ng/ml sodium selenite, 63 μg/mlN-acetylcysteine, 5 μM forskolin, 50 units/ml penicillin, and 50 μg/mlstreptomycin (GIBCO), as well as one or both of 10 ng/ml bFGF and 10ng/ml PDGF, or one or both of bFGF (10 ng/ml) and EGF (10 ng/ml).

In all experiments, cells were maintained in 100-mm culture dishes(Nunc) or culture flasks (Iwaki Glass) at 37° C. in a humidified 5%CO₂/95% air atmosphere.

Flow Cytometry

To identify and isolate the SP cells in the cancer cell lines, the lineswere cultured as described above, in either FCS or serum-free culturemedium with bFGF, PDGF, or both. The cells were removed from the culturedish with trypsin and EDTA GIBCO BRL), washed, suspended at 10⁶ cellsper ml in DMEM containing 2% FCS (staining medium), and preincubated in1.5-ml Eppendorf tube at 37° C. for 10 min. The cells were then labeledin the same medium at 37° C. for 90 min with 2.5 μg/ml Hoechst 33342 dye(Molecular Probes), either alone or in combination with 50 μM verapamil(Sigma), which is an inhibitor of some (verapamil-sensitive) ABCtransporters (Goodell, M. A. (1996) J. Exp. Med. 183 1797-1806.).Finally, the cells were counterstained with 1 μg/ml propidium iodide tolabel dead cells. Then, 3-5×10⁴ cells were analyzed in a FACSVantagefluorescence-activated cell sorter (Becton Dickinson) by usingdual-wavelength analysis (blue, 424 144 nm; red, 675 nm) afterexcitation with 350-nm UV light. Propidium iodide-positive dead cells(15%) were excluded from the analysis. In the case of the C6 cell line,the SP cells or non-SP cells were sorted and cultured in serum-freeculture medium with bFGF and PDGF.

RNA Extraction and RT-PCR Assay

Cells were harvested, and poly(A)+ RNA was prepared by using a QuickPrepMicro mRNA purification kit (Amersham Biosciences) and reversetranscribed by using a First-Strand cDNA synthesis kit (AmershamBiosciences), as described (Kondo, T. & Raff, M. (2000) Science 289,1754-1757). The RT-PCR was carried out in a 20 μl reaction mixture thatcontained 1 μl of cDNA as template, 1 μM specific oligonucleotide primerpair, and 0.5 unit of Taq DNA polymerase (Takara Shuzo, Kyoto).

Cycle parameters for bcrp, mdr1, or g3pdh cDNAs were 30 sec at 94° C.,30 sec at 60° C., and 60 sec at 72° C. for 33, 32, and 25 cycles,respectively. The identity of the amplified products was checked bydigestion with appropriate restriction enzymes. Oligonucleotide DNAprimers were synthesized as follows. For rat bcrp, sequences conservedbetween human and mouse were used: 5′-CCAGTTCCATGGCACTGGCCATA-3′ (SEQ IDNO:1) and 5′-CAGGGCCACATGATTCTTCCACA-3′ (SEQ ID NO:2).

For rat mdr1, sequences conserved between human and mouse were used:5′-GCAAAGCTGGAGAGATCCTCACCA-3′ (SEQ ID NO:3) and5′-CAACATTTTCATTTCAACAACTCCTGC-3′ (SEQ ID NO:4).

For rat g3pdh, the following sequences were used:5′-ACCACAGTCCATGCCATCAC-3′ (SEQ ID NO:5) and 5′-TCCACCACCCTGTTGCTGTA-3′(SEQ ID NO:6).

For other RT-PCR experiments, the following forward and reverse primerswere used:

Notch 1: (SEQ ID NO: 7) 5-AGCCTCAACATCCCCTACAAG-3 and (SEQ ID NO: 8)5-CAGTCGGCGTCAACCTCACC-3; Notch 2: (SEQ ID NO: 9)5-AGAAACAGAGGATGACACGCAG-3 and (SEQ ID NO: 10) 5-GCTTACGCTTTCGTTTTGCC-3;Notch 3:    (SEQ ID NO: 11) 5-ATGGTGGAAGAGCTCATCGC-3 and (SEQ ID NO: 12) 5-TGGCCTCCTGCTCTTCTTGG-3; Notch 4: (SEQ ID NO: 13)5-TGTGGCTGCCCCCTGGTTTCA-3 and  (SEQ ID NO: 14)5-GTGTCACCCCATCAGGTCCAC-3; Hes1: (SEQ ID NO: 15)5-CCATGCCAGCTGATATAATGGAGAAAAA-3 and  (SEQ ID NO: 16)5-AATCAGTTCCGCCACGGCCTCCA-3; Hes3:  (SEQ ID NO: 17)5-AGGTCTCTTCTGGAGAGACACT-3 and (SEQ ID NO: 18) 5-CGCTGTCCGTGGTGCTGCCT-3;Hes5: (SEQ ID NO: 19) 5-CGACTGCGGAAGCCGGTGGT-3 and (SEQ ID NO: 20)5-AGCAGCTTCATCTGCGTGTCG-3 frz1: (SEQ ID NO: 21)5-CGGGCAGCAGTACAACGGCGA-3 and (SEQ ID NO: 22) 5-GTTCTGGCCCACGCACAGCTC-3;frz3: (SEQ ID NO: 23) 5-GGAATATGGACGTGTCACACT-3 and  (SEQ ID NO: 24)5-GCGAGCAAATGACAGTTCTTC-3; frz4: (SEQ ID NO: 25)5-TGAGACTAGTGGATGCCGATG-3 and (SEQ ID NO: 26)5-CCCTCTTCTCTCTCTTTACCTT-3; frz5: (SEQ ID NO: 27)5-CCAGGAAATCACGGTGCCCA-3 and (SEQ ID NO: 28) 5-CGGTCGCAGCTCATGCGCTC-3;frz7: (SEQ ID NO: 29) 5-ACACGAACCAAGAGGACGCG-3 and (SEQ ID NO: 30)5-GAGCCGTCGGACGTGTTCTG-3; wnt1: (SEQ ID NO: 31)5-GAGTGCAAATGCCACGGGATG-3 and (SEQ ID NO: 32) 5-AGCTGACGTGGCAGCACCAG-3;wnt10: (SEQ ID NO: 33) 5-CCGCTGACGGCCAACACCGT-3 and (SEQ ID NO: 34)5-ATCCCGAGAGAACTTCTCTCC-3; wnt11: (SEQ ID NO: 35)5-CTGATGCGTCTACACAACAG-3 and  (SEQ ID NO: 36) 5-GCAGAAGTCAGGGGAGCTCTG-3;gli1: (SEQ ID NO: 37) 5-AGGGCAGCTCAAGGCTCAGC-3 and (SEQ ID NO: 38)5-TCATCTAGGATAGCCACAAAG-3; gli2: (SEQ ID NO: 39)5-CAGCAGAGGCTGTGCCCAAGG-3 and (SEQ ID NO: 40) 5-GCGTGAGGAATTCTGGGAGA-3;gli3: (SEQ ID NO: 41) 5-GTGGGCTTCAGTCAGCAAGAC-3 and (SEQ ID NO: 42)5-CTGCAAGGAACTTGCTTTCTT-3; Patch: (SEQ ID NO: 43)5-TCTGCTGGGTGTACTGATGC-3 and (SEQ ID NO: 44) 5-AGAGTCCAGGTGGGGCTGTT-3;Smo: (SEQ ID NO: 45) 5-CCTCCTGGTGGAGAAGATCAA-3 and (SEQ ID NO: 46)5-CTGGGGAGATCTCTGCCTCA-3; Shh:  (SEQ ID NO: 47) 5-GCCATCATTCAGAGGAGTCTC-3  and  (SEQ ID NO: 48)5-CACGAAGAGCAGGTGCGCGG-3; hiwi: (SEQ ID NO: 49)5-CATCAATGAAGGGATGACCCG-3 and (SEQ ID NO: 50) 5-TCTCACTGCCTGGCTCACGAT-3;Nucstem: (SEQ ID NO: 51) 5-TTCCATGGGACTTACAAGGAG-3 and  (SEQ ID NO: 52)5-AGGCACCTGTCCACTCAGACC-3;  bmi1: (SEQ ID NO: 53)5-ATGCATCGAACAACCAGAAT-3 and (SEQ ID NO: 54) 5-TCACTTTCCAGCTCTCCA-3;musashil: (SEQ ID NO: 55) 5-CCTGGTTACACCTACCAGTTC-3 and (SEQ ID NO: 56)5-TCAGTGGTACCCATTGGTGAAG-3; oct4: (SEQ ID NO: 57)5-CTGCTGAAGCAGAAGAGGATCAC-3 and (SEQ ID NO: 58)5-CTTCTGGCGCCGGTTACAGAACCA-3; prominin1: (SEQ ID NO: 59)5-AGGCTACTTTGAACATTATCTGCA-3 and (SEQ ID NO: 60)5-GGCTTGTCATAACAGGATTGT-3; integrin alpha-6: (SEQ ID NO: 61)5-GAGTTCAGTTTCGAAACCAAG-3 and (SEQ ID NO: 62) 5-GCCATTCTGGTTGGCAACACA-3;ER-alpha: (SEQ ID NO: 63) 5-GCTGCCAACCTTTGGCCAAG-3 and  (SEQ ID NO: 64)5-CCTTCTCTTCCAGAGACTTCA-3; ER-beta: (SEQ ID NO: 65)5-AAGAGGGATGCTCACTTCTGC-3 and  (SEQ ID NO: 66) 5-CCCTCATCCCTGTCCAGAAC-3;Mucin1(EMA): (SEQ ID NO: 67) 5-GTACCATCAATGTCCACGAC-3 and(SEQ ID NO: 68) 5-CTACGATCGGTACTGCTAGG-3; CK14: (SEQ ID NO: 69)5-GTGACCATGCAGAACCTCAA-3 and  (SEQ ID NO: 70) 5-TGCTGAGCTGGGACTGCAGCT-3;CK18: (SEQ ID NO: 71) 5-AAGGTCATTGATGACACCAATA-3 and (SEQ ID NO: 72)5-GGATGGTTTGCATGGAGTTG-3; and CK19: (SEQ ID NO: 73)5-GACAAGATTCTTGGTGCCAC-3 and (SEQ ID NO: 74) 5-GACTGCAGCTCAATCTCAAG-3.

Immunostaining of Cultured Cells

To examine the expression of neuronal, glial, and other stem cellmarkers in C6 and MCF-7 SP cells cultured for 1 or 10 days, the cellswere cultured overnight in chamber slides (Nunc) precoated with 1 μg/mlfibronectin (Invitrogen) and 15 μg/ml ornithine (Sigma). The cells werefixed with 2% parafonnaldehyde for 10 minutes at room temperature,treated with 20% FCS, and then stained with the following mousemonoclonal antibodies: anti-GFAP (1:200; Sigma), anti-β-III tubulin(1:200; Sigma), anti-microtubule-associated protein 2 (MAP2; 1:500;Sigma), anti-BCRP (1:100; Pharmingen), anti-CD133 (1:100; Pharmingen),rat monoclonal anti-Notch 1 (bTAN20; diluted 1:100, DevelopmentalStudies Hybridoma Bank), rat monoclonal anti-Notch 2 (C651.6DbHN;diluted 1:100, Developmental Studies Hybridoma Bank) and anti-nestin(1:200; Pharmingen).

The primary antibodies were detected with Texas red-conjugated goatanti-mouse IgM or IgG (1:100; Jackson ImmunoResearch) as described(Kondo, T. & Raff, M. (2000) Science 289, 1754-1757), with the exceptionof the Notch antibodies, which were detected with primary antibodieswere detected with Alexa-dye conjugated secondary antibodies (1:200,Molecular Probes). Also, antibodies specific for BCRP and CD133 weredetected with FITC-conjugated goat anti-mouse IgG. The cells werecounterstained with Hoechst 33342 to identify all nuclei.Immunoreactivity was determined by immunofluorescence microscopy.

Transplantation into Nude Mice

KSL_slc nude mice were purchased from SLC (Shizuoka, Japan). FACS-sortedC6 SP and non-SP cells were cultured for 7 days in bFGF plus PDGF, and10⁵ cells of each type were injected i.p. into three 4-week-old femalenude mice. The same experiment was repeated twice with similar results.The mice were killed 18 days after injection and examined for tumors, asdescribed below. Mice were treated according to the guidelines of theKumamoto University Animal Committee.

Hematocrit Analysis

Blood was collected in EDTA at a final concentration of 1 mM. Glassmicrocapillary tubes (Hirschmann) were filled with blood, capped withParafilm, and centrifuged at 3,000×g for 1 minute, and the hematocritwas calculated as the proportion of the tube containing erythrocytes.

Immunostaining of Tissue Sections

Tumor-bearing tissues were fixed in 4% paraformaldehyde, embedded inTissue-Tek OCT optimal cutting temperature) compound, and then frozen at20° C. Cryostat sections (12 μm) were cut, mounted onpoly-L-lysine-coated slides, and air-dried for 24 hours. To characterizethe cells in tumors, the sections were treated with 10% normal goatserum (DAKO) for 30 minutes at room temperature and then stained withthe following mouse monoclonal antibodies: antinestin antibody,anti-GFAP antibody, and anti-low molecular weight neurofilament antibody(1:200; Sigma). The primary antibodies were detected with Alexa594-conjugated goat antimouse IgG (1:200; Molecular Probes). The cellswere counterstained with Hoechst 33342 to identify all nuclei. Thestained sections were examined and photographed in an AX70 fluorescencemicroscope (Olympus, Orangeburg, N.Y.).

Treatment of Cell Lines with Gamma Secretase Inhibitor

MCF-7 cells were cultured in serum-containing media, as described above.Cells were harvested from the cultures, washed, and resuspended in gammasecretase inhibitor I. Gamma secretase inhibitor I was purchased fromCalbiochem™ (San Diego, Calif.; Catalog number 565750). The gammasecretase inhibitor was added to the cultures at a final concentrationof 1 uM. Cells were treated for 7 days, and the SP was quantitated asdescribed.

Results

Many Cancer Cell Lines Contain a Small SP

To determine whether any of the six established cancer cell lines in ourcollection contained SP cells, cells were removed from the culturedishes with trypsin and EDTA and stained with the fluorescent dyeHoechst 33342, which has been shown to be extruded actively by the SPcells in various tissues by means of verapamil-sensitive ABCtransporters. They were then analyzed by flow cytometry. As shown inFIGS. 1A-1D, the C6 glioma cells contained 0.4% SP cells (FIG. 1A), theMCF7 breast cancer cells contained 2.0% SP cells (FIG. 1B), the B104neuroblastoma cells contained 0.4% SP cells (FIG. 1C), and the HeLacarcinoma cells contained 1.2% SP cells (FIG. 1D). In each case, the SPwas decreased greatly by treatment with verapamil, indicating that thepopulations were bona fide SPs (see FIGS. 1E-H). Thus, some cancer celllines contain a small SP, despite having been maintained in culture formany years. No SP cells were detected in the two human osteosarcomalines (U-20S and SaOS-2).

C6 SP Cells can be Expanded in bFGF Plus PDGF

PDGF is the main mitogen for oligodendrocyte precursor cells (Noble, M.et al (1988) Nature 333, 560-562.), whereas bFGF is a major mitogen forNSCs (Nurcombe, V. et al (1993) Science 260, 103-106). Unfractionated C6cells were cultured on uncoated dishes in 10% FCS or in serum-freeculture medium with PDGF, bFGF, or both.

The morphology of the cells was found to be very different in thedifferent culture conditions. In FCS or bFGF alone, the cells had aflat, fibroblast-like shape. In PDGF, they had a round body but werestill attached to the dish. In the presence of both after 10 days, justas CNS NSCs do under similar conditions (Chiasson, B. J. et al (1999) J.Neurosci. 19, 4462-4471).

The cells were stained with Hoechst 33342 and analyzed by flowcytometry. When cultured in serum-free medium with both PDGF and bFGF,SP cells were maintained, and their proportion increased with time(FIGS. 2D and 3). By contrast, when cultured in either bFGF or PDGFalone, the C6 cells survived and proliferated, but by 3 weeks few SPcells could be detected (FIGS. 2B, 2C, and 3). These findings indicatethat C6 SP cells can expand in a combination of bFGF and PDGF but cannotbe maintained in either growth factor alone.

The expression of bcrp mRNA, which encodes a verapamil sensitive ABCtransporter, as well as mdr1 mRNA, which encodes another ABCtransporter, was examined in C6 cells cultured in the four conditionsdescribed above.

bcrp mRNA expression was detected in the presence of both PDGF and bFGFbut not in FCS or in bFGF or PDGF alone. In contrast, mdr1 mRNA wasexpressed in FCS, bFGF, or bFGF plus PDGF, although it was not expressedin PDGF alone. Together, these data indicate that BCRP, but not MDR1, isresponsible for the SP character of some C6 cells.

To investigate the individual roles of PDGF and bFGF in expanding C6 SPcells, C6 cells were cultured in either bFGF or PDGF for 2 weeks andthen in bFGF plus PDGF for an additional 2 weeks. The cells were thenstained with Hoechst 33342 and analyzed by flow cytometry. As shown inFIGS. 4A-4C, 1.8% of the cells cultured in bFGF and then in bFGF plusPDGF were SP cells. By contrast, although there seemed to be SP cellsafter culturing in PDGF and then in bFGF plus PDGF, these cells werestill seen when stained in the presence of verapamil (FIGS. 4D-4F),indicating that they were not bona fide SP cells. The expression of bothbcrp and mdr1 mRNA in C6 cells cultured was also examined under thesetwo conditions. As shown in FIG. 4D, bcrp mRNA was detected in the cellsthat were cultured in bFGF and then in PDGF plus bFGF, but not in thecells cultured in PDGF and then in PDGF plus bFGF; by contrast, mdr1mRNA was detected in both conditions. It is possible, therefore, thatbFGF on its own maintains C6 SP cells at an undetectable low level andthat PDGF stimulates the proliferation of these cells.

MCF7 Cell Expansion

MCF7 cells were cultured in 10% FCS (FIG. 7A) or in serum-free culturemedium with bFGF (FIG. 7B), EGF (FIG. 7C), or both (FIG. 7D) for 7 days.In FCS, the cells had a flat and fibroblast-like shape, however, in theserum-free medium, they formed floating aggregates, known asmammospheres (Dontu, G. et al (2003) Genes Dev. 17, 1253-1270.). Cellswere stained with Hoechst dye and analyzed by flow cytometry. Whencultured in FCS, less than 0.8% of the cells are SP cells. By contrast,when cultured_:in serum-free medium with bFGF, EGF or both, 5.1%, 3.5%,or 6.2% of the cells, respectively, are SP cells. This indicates thatMCF7 SP cells significantly expand in serum-free medium supplementedwith bFGF and EGF.

C6 SP Cells can Repopulate Both SP and Non-SP C6 Cells.

To compare the ability of C6 SP cells with the ability of non-SP cellsto produce SP cells, C6 cells were cultured without FCS and in PDGF plusbFGF for 2 weeks, stained with Hoechst 33342, and sorted into SP andnon-SP fractions by flow cytometry. The SP and non-SP cells were thenexpanded separately in the same medium for an additional 2 weeks. Asthey proliferated, the cells in the two populations had differentmorphologies. The cells in the SP cultures formed floating spheres,whereas the cells in the non-SP cultures remained attached to theculture dishes and had a fibroblast-like morphology. When the cells werere-stained with Hoechst 33342 and re-analyzed by flow cytometry, it wasfound that the cultures initiated with SP cells contained both SP andnon-SP cells, whereas the cultures initiated with non-SP cells containedonly non-SP cells (FIG. 5).

These data are consistent with previous findings that only the SP cellsin primary neurospheres can produce both SP and non-SP cells in culture(Hulspas, R. & Quesenberry, P. J. (2000) Cytometry 40, 245-250).Furthermore, when single FACS-sorted SP cells were cultured alone in thesame medium in a well of a 98-well culture plate, 70% of the cellsproliferated and reformed floating spheres; in contrast, single non-SPcells cultured in the same way proliferated much more slowly, and almostall of the cells died by 3 weeks. Thus, C6 SP cells, but not non-SPcells, can form floating spheres, proliferate extensively, and produceC6 SP cells in culture.

C6 SP Cells can Produce Both Neurons and Glia in Culture

SP cells were sorted, cultured for 1 or 10 days in PDGF plus bFGF onornithine-fibronectin-coated chamber slides, and then immunolabeled forneuronal and glial markers. After 1 day, 90% of the cells were labeledfor the NSC marker nestin (92+/−2%), but none were labeled for theneuronal markers MAP2 or β-III tubulin or the astrocyte marker GFAP,suggesting that C6 SP cells might be undifferentiated NSC-like cells.After 10 days, however, 70% were immunolabeled for β-III tubulin, 5% forMAP2, and 7% for GFAP. Thus, C6 SP cells can generate both neurons andglial cells in culture.

The Malignancy of C6 Cells In Vivo is Largely Dependent on the SP Cells

To address whether SP and non-SP C6 cells differ in their malignancy, C6cells growing in PDGF plus bFGF were sorted into SP and non-SP cells,expanded in the same medium for 1 week, and then 10⁵ cells from eitherpopulation were injected i.p. into nude mice.

After 18 days, all mice injected with cells from the SP cultures showedintraabdominal hemorrhages (FIG. 6) and tumor invasion into themesentery, uterus and lymph nodes. In four of six mice, there was alsotumor invasion into the lungs. In contrast, after the same period, thecells from non-SP cultures had not formed tumors that invaded into thesetissues, although we detected one s.c. tumor and an occasional smallmetastasis in mesenteric lymph nodes.

Thus, much of the malignancy of the C6 line depends on SP cells. Todetermine whether C6 cells could produce neurons and glia in vivo, thetumor-bearing tissues were fixed in 4% paraformaldehyde, and frozensections cut and immunolabeled for neuronal and glial markers.

35% of the cells in the tumors were immunolabeled for nestin, 30% forGFAP, and 15% for the neuronal marker NF-L (low molecular weightneurofilament), indicating that C6 SP cells can differentiate into bothneurons and glia in vivo.

Identification of Cell Line-Derived Cancer Stem Cells by Binding ofMonoclonal Antibodies

In cancer cell lines, cell line-derived cancer stem cells can also beidentified using monoclonal antibodies that specifically bind to surfaceproteins. SP and non-SP cells were isolated by flow cytometry, spun ontochamber slides, and fixed, as described above. Cells were then incubatedwith fluorescently-labeled antibodies specific for BCRP (FIG. 9A), CD133(FIG. 9B), Notch 1 (FIG. 9C), and Notch 2 (FIG. 9D). Nuclei werecounterstained with propidium iodide or Hoechst 33342, as indicated. Thepercentage of cells from each population that were bound by theantibodies was quantitated using fluorescence microscopy, with a minimumof 1000 total cells counted for each population. The results demonstratethat each of the antibodies tested binds to the majority of SP cells,and not the non-SP cell population, as shown in FIGS. 9E-H. Therefore,Hoechst staining or antibodies can be used to specifically recognizecell line-derived cancer stem cells.

Analysis of Gene Expression of Cancer Stem Cell Markers in CellLine-Derived Cancer Stem Cells

In another embodiment of the invention, cell line-derived cancer stemcells can be isolated from cancer cell lines using gene expressionanalysis. SP and non-SP cell were isolated from the MCF-7 breast cancercell line. RNA was then isolated using standard protocols. Certainfamilies of genes were selected for analysis based on their role incancer biology, or their known function in normal stem cells. Thesefamilies include the molecules involved in the Wnt pathway, the Notchpathway, and the Hedgehog (HH) pathway. Also, genes for various stemcell and differentiation markers were also tested. Primers were designedbased on the sequences of these genes as set forth above, and RT-PCR wasperformed. Results indicate that Wnt10, Wnt11, Notch 1, Notch 2, Notch3, and prominin-1 have increased expression in the SP cells relative tonon-SP cells (see FIGS. 8A-8E). These data can be readily used to designpromoter-reporter constructs to be employed in drug screens to discoveranti-cancer stem cell compounds. For example, the promoter of the Wnt10gene could be fused with the gene encoding green fluorescent protein(GFP) to create a chimeric gene that specifically expresses GFP in thecell line-derived cancer stem cell population of MCF-7. Compounds can betested for activity using the GFP-transfected cell line, and cellline-derived cancer stem cell death can be measured usingfluorescently-labeled markers of apoptosis, such as Annexin.

Treatment of Cell Lines with Gamma Secretase Inhibitor I

The invention includes methods for evaluating compounds for anti-cancerstem cell activity by monitoring the SP cell population of a cancer cellline. In this experiment, MCF-7 cells were treated with a gammasecretase inhibitor, as described above. The Notch pathway has beenshown to promote the self-renewal of stem cells, and gamma secretaseactivates this pathway by cleaving the Notch protein (De Strooper etal., Nature 398: 518-522 (1999), Mumm et al., Molecular Cell. 5: 197-206(2000)). Therefore, gamma secretase inhibitors could affect cancer stemcells expressing the Notch protein. FIGS. 10A-10D shows that MCF-7 cellstreated with 1 uM gamma secretase inhibitor for 7 days results in theexpansion of the SP cell population from 1.1% to 21%. As expected, inthe presence of reserpine, BCRP is inhibited, and no SP is visible. Asdescribed above, the SP corresponds with the cancer stem cells within acell line. Therefore, these results validate the method of monitoringthe SP cell population fate, whether positive or negative, in cancercell lines while screening compounds for potential anti-cancer stem cellactivity. While it was expected that a gamma secretase inhibitor mightdecrease the SP, instead this assay demonstrated that under theseconditions, this gamma secretase inhibitor caused an increase in the SP.These findings indicate that gamma-secretase inhibitors candifferentially affect SP versus non-SP cells. Given that Notch has beendescribed as both a tumor suppressor and an oncogene, and that Notch isa target of gamma-secretase inhibitors, then treatment of a cancer cellline with a gamma secretase inhibitor may ultimately affect differentcellular phenotype outcomes (Nature Reviews Cancer 3: 756-767 (2003)),This demonstrates that a gamma-secretase inhibitor such as the onedescribed herein may either increase SP or decrease SP depending on theactivity of Notch in any given system. Thus, the differential effect onSP versus non-SP cells by the gamma secretase inhibitor (FIG. 10A-10D)indicates that certain gamma secretase inhibitors may negatively affectcancer stem cells in certain contexts, while others of this class maynot under the same conditions. In addition, compounds of other classes,not necessarily inhibiting gamma-secretase, are expected by theseresults to differentially affect the SP and in certain cases have anegative effect on SP—an effect that can be readily identified throughthese same screening methods.

CONCLUSION

The above described findings illustrate that cancer stem cells may bepresent in cancer cell lines in culture, even when the cell lines havebeen maintained for many years. An SP was detected in four of the sixcancer cell lines tested, and in most normal tissues, the stem cells arefound in the SP. In addition, cell line-derived cancer stem cells canalso be detected using antibodies to cell surface markers. In the MCF-7cell line, BCRP, CD133, Notch 1, and Notch 2 were differentiallyexpressed by the SP cell population, and therefore each can be used toidentify cell line-derived cancer stem cells in this cell line. Also,these results demonstrate that gene products that are differentiallyexpressed in cell line-derived cancer stem cells can also be identifiedby RT-PCR. This includes cell surface proteins as well as intracellularproteins. The promoters of genes differentially expressed by cellline-derived cancer stem cells can be used to create promoter-reporterconstructs in order to force the expression of detectable proteins, suchas green fluorescent protein or luciferase, that enable theidentification of the cell line-derived cancer stem cell populationwithin the cell line. As taught by the invention, each of thesestrategies enables the use of cancer cell lines in drug screens,including high throughput screens, and in the testing of compoundsidentified using these screens, for anti-cancer stem cell activity.

The SP of the C6 glioma line, which comprises only 0.4% of the cellsmaintained in serum, has a number of characteristics that are expectedof cancer stem cells. The SP cells in culture can self-renew and produceboth SP and non-SP C6 cells, whereas the non-SP cells under the sameculture conditions can produce non-SP cells only. Also, the C6 SP cellsin culture can form neurospheres and produce neurons as well as glialcells, indicating that they have normal stem cell-like properties.Finally, the C6 SP cells produce tumors in nude mice with highefficiency, whereas the non-SP C6 cells do not.

In summary, the present invention illustrates the importance of cellline-derived cancer stem cells and provide methods for isolating them.The invention also illustrates that cancer cell lines are importantmodels for studying the basic biology of stem cells. The inventionfurther provides methods for using cancer cell lines as a source ofcancer stem cells to evaluate test compounds for anti-cancer stern cellactivity in drug screens, including high throughput screens. Inaddition, the invention teaches the development and use of assays thatenable the testing of compounds for anti-cancer stern cell activity. Theinvention also provides methods for using cancer stem cells isolatedfrom cell lines in the testing of compounds for anti-cancer stern cellactivity.

1. A method of identifying and/or obtaining a cell line-derived cancerstem cell comprising; providing a population of cancer cells from acultured cancer cell line, and; determining the presence of a cancerstem cell marker in one or more cells in the population, to therebyidentify and/or obtain a cell line-derived cancer stem cell. 2.-27.(canceled)
 28. A method of identifying a cancer stem cell markercomprising; comparing a level or amount of one or more polypeptides in acancer stem cell obtained from a population of cultured cancer cells bythe method of claim 1 with a level or amount of the one or morepolypeptides in a non-cancer stem cell, and; identifying a polypeptidefrom the one or more polypeptides whose level or amount is increased inthe cancer stem cell relative to the non-cancer stem cell as a cancerstem cell marker polypeptide. 29.-62. (canceled)
 63. A method for theidentification of a compound that inhibits the growth, viability, and/orproliferation of cell line-derived cancer stem cells in a cancer cellline comprising: (i) contacting the cancer cell line with one or moretest compounds, wherein the cancer cell line comprises cell line-derivedcancer stem cells and tumor bulk; (ii) determining the effect of the oneor more test compounds on the growth, viability, and/or proliferation ofcell-line derived cancer stem cells in the cancer cell line anddetermining the effect of the one or more test compounds on the growth,viability and/or proliferation of cells from the tumor bulk in thecancer cell line; and (iii) comparing the effect of the one or more testcompounds on the growth, viability, and/or proliferation of cellline-derived cancer stem cells in the cancer cell line with the effectof the one or more test compounds on the growth, viability, and/orproliferation of cells from the tumor bulk in the cancer cell line,wherein a test compound is identified as a compound that inhibits thegrowth, viability, and/or proliferation of cell line-derived cancer stemcells if it: (a) inhibits the growth, viability, and/or proliferation ofthe cell line-derived cancer stem cells in the cancer cell line but doesnot inhibit the growth, viability, and/or proliferation of cells fromthe tumor bulk in the cancer cell line; or (b) inhibits the growth,viability, and/or proliferation of the cell line-derived cancer stemcells in the cancer cell line and also inhibits the growth, viability,and/or proliferation of cells from the tumor bulk in the cancer cellline. 64.-71. (canceled)
 72. A method for treating cancer in a subjectcomprising administering the compound of claim 63 to the subject. 73.The method of claim 63, wherein the growth, viability, and/orproliferation of the cell line-derived cancer stem cells is monitoredusing a detectable marker for cell death, proliferation, and/ordifferentiation.
 74. The method of claim 73, wherein the detectablemarker is Annexin or propidium iodide.
 75. The method of claim 63,wherein the effect of the one or more test compounds on the growth,viability, and/or proliferation of the cell line-derived cancer stemcells and tumor bulk is determined by monitoring the binding of thecompound to the cell line-derived cancer stem cells.
 76. The method ofclaim 63, wherein the effect of the one or more test compounds on thegrowth, viability, and/or proliferation of the cell line-derived cancerstem cells and tumor bulk is determined by monitoring the expression oractivity of one or more cell line-derived cancer stem cell markers. 77.The method of claim 63, wherein the expression or activity of one ormore cell line-derived cancer stem cell markers is monitored by adetectable reporter that is specifically expressed by the cellline-derived cancer stem cells and not by the cells from the tumor bulkin the cancer cell line.
 78. The method of claim 77, wherein a gene forthe detectable reporter is linked to a promoter, and wherein thepromoter belongs to a cell line-derived cancer stem cell marker.
 79. Themethod of claim 78, wherein the one or more cell line-derived cancerstem cell markers comprise stem cell factor, SCF ligand, c-Kit ligand,telomerase, TRA-1-60, TRA-1-81, vimentin, genesis, germ cell nuclearfactor, hepatocyte nuclear factor-HNF-4, nestin, breast cancerresistance protein (BCRP), verapamil, NG2, A2B5, polysialylated form ofneuronal cell-adhesion molecule (PSA-NCAM), nucleostemin, sox-2,musashi-1 and -2, hairy and enhancer-of-splits (Hes-1, -3, -5), melk,PSP, Inhibitor of differentiation (Id-1, -2, -3, -4), Bmi-1, brca-1,Oct-4, Nanog, FGF-4, Pax6, Stage-specific embryonic antigens (SSEA-1,-3, -4), Cluster designation 30 (CD30), CD34, CD44, Notch, CD123, CD133,CD24, Cripto (TDGF-1) ATA-4 gene, GCTM-2, Alkaline phosphatase,Alpha-fetoprotein (AFP), Bone morphogenetic protein-4, mdr-1, hiwi,prominin-1, Brachyury, Wnt1, Wnt10, Wnt11, Notch 1, Notch 2, Notch 3,Notch 4, integrin alpha-6, mucin-1 (EMA), estrogen receptor-alpha,estrogen receptor-beta, cytokeratin-14, cytokeratin-18, and cytokeratin19.
 80. The method of claim 79, wherein the cell line-derived cancerstem cell marker is Oct-4.
 81. The method of claim 77, wherein thedetectable reporter is a fluorescent reporter.
 82. The method of claim81, wherein the detectable reporter is green fluorescent protein (GFP)or luciferase.
 83. The method of claim 77, wherein the effect of the oneor more test compounds on the growth, viability, and/or proliferation ofthe cell line-derived cancer stem cells and cells from the tumor bulk inthe cancer cell line is determined by monitoring the expression oractivity of the detectable reporter.
 84. The method of claim 63, whereinthe effect of the one or more test compounds on the growth, viabilityand/or proliferation of the cell line-derived cancer stem cells andtumor bulk is determined using at least one of the following techniques:flow cytometry, fluorimetry, microscopy, immunofluorescence, ELISA,radioimmunoas say, immunoenzymatic assay, fluorescence activated cellsorting (FACS), PCR, RT-PCR, differential display, representationaldifference analysis, microarray, suppressive subtractive hybridization,direct sequencing, Western blotting, immunohistochemical staining, andimmunocytochemical staining.
 85. The method of claim 63, wherein thecell line is a human cell line.
 86. The method of any one of claim 63,wherein the cell line is one of the following: HeLa cells, MCF-7 cells,C6 cells, or B104 cells.
 87. The method of claim 63, wherein the cellline is a prostate cancer cell line, an adenocarcinoma cell line, a lungcancer cell line, a gastrointestinal cancer cell line, a colon cancercell line, a breast carcinoma cell line, an ovarian carcinoma cell line,a testicular cancer cell line, a glioma cell line, a liver cancer cellline, a kidney cancer cell line, a bladder cancer cell line, apancreatic cancer cell line, a brain cancer cell line, a neuroblastomacell line, a sarcoma cell line, an osteosarcoma cell line, a melanomacell line, a lymphoma cell line, a retinoblastoma cell line, a skincancer cell line, or a leukemia cell line.